Dr. Epperla Discusses the Current Treatment of MCL

Narendranath Epperla, MBBS, MS
Published: Wednesday, Oct 18, 2017



Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the current treatment landscape of patients with mantle cell lymphoma (MCL).

Upfront treatment for MCL continues to be induction therapy followed by autologous stem cell transplant, says Epperla. This is based on the long term follow-up data from the NORDIC trial.

In the relapsed/refractory setting, there are many agents to choose from—BTK inhibitors, PI3-kinase inhibitors, and immunomodulatory agents. Epperla says these agents can be used in various combinations.
 


Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the current treatment landscape of patients with mantle cell lymphoma (MCL).

Upfront treatment for MCL continues to be induction therapy followed by autologous stem cell transplant, says Epperla. This is based on the long term follow-up data from the NORDIC trial.

In the relapsed/refractory setting, there are many agents to choose from—BTK inhibitors, PI3-kinase inhibitors, and immunomodulatory agents. Epperla says these agents can be used in various combinations.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x